Drug Trial Radar · NCT06358573
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
61
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
Oct 2028
Study completion Dec 2031
Sponsor
- Lead sponsor
- Swiss Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for individuals with TNBC to achieve a so-called pathologic complete response (pCR) to treatment. In the phase II study SAKK 66/22, it is being investigated whether the administration of the drug INT230-6 before surgery for breast cancer can increase the rate of pCR in the tumor and affected lymph nodes. The tolerability of INT230-6 as well as other factors such as response to treatment and the possibility of breast-conserving surgery are also being examined.
Conditions
- Triple-negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
Interventions
INT230-6Drug
INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate. The IMP is without marketing authorization in Switzerland and anywhere in the world.
neoadjuvant immuno-chemotherapyOther
Standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR) in the primary tumor (ypT0/Tis) and affected lymph nodes (ypN0).Time frame: At the date of tumor assessment after surgery, estimated at 29 to 32 weeks after treatment start for cohort A and at 27 to 30 weeks after treatment start for cohort B.
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Centre de lutte contre le cancer Léon Bérard
Lyon, France · Recruiting
Tumor Zentrum Aarau
Aarau, Switzerland · Terminated
St. Claraspital
Basel, Switzerland · Recruiting
EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni
Bellinzona, Switzerland · Recruiting
Kantonsspital Graubünden
Chur, Switzerland · Recruiting
Kantonsspital Baselland
Liestal, Switzerland · Recruiting
HOCH Health Ostschweiz
Sankt Gallen, Switzerland · Recruiting
TBZO - Tumor- & Brustzentrum Ostschweiz
Sankt Gallen, Switzerland · Active not recruiting
Kantonsspital Winterthur
Winterthur, Switzerland · Recruiting
Universitätsspital Zürich - Klinik für Gynäkologie
Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.